Glen Cangelosi, MD
Ophthalmology · New Orleans, LANPI 1326048398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 197 payments — averaging $31.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Bausch & Lomb Americas Inc.$876
- AbbVie$774
- Johnson & Johnson Surgical Vision, Inc.$762
- Bausch & Lomb, A Division Of Bausch Health US, LLC$470
- Ivantis, Inc$399
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,227100%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 34 | $1,260 |
| Bausch & Lomb Americas Inc. | 30 | $876 |
| AbbVie(2 entities) | 37 | $774 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $762 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 25 | $470 |
| Ivantis, Inc | 4 | $399 |
| Aerie Pharmaceuticals, Inc. | 12 | $256 |
| Glaukos Corporation | 3 | $248 |
| Beaver-visitec International, Inc. | 4 | $197 |
| Novartis | 6 | $150 |
| Tarsus Pharmaceuticals, Inc. | 1 | $122 |
| Mallinckrodt Hospital Products Inc. | 4 | $91 |
| NEW World Medical,inc. | 2 | $90 |
| Kala Pharmaceuticals, Inc. | 4 | $67 |
| Sun Pharmaceutical Industries Inc. | 3 | $65 |
| Shire North American Group Inc | 3 | $62 |
| Carl Zeiss Meditec, Inc. | 2 | $57 |
| Omeros Corporation | 1 | $57 |
| Oyster Point Pharma, Inc. | 2 | $51 |
| Apellis Pharmaceuticals, Inc. | 1 | $48 |
| Eyevance Pharmaceuticals LLC | 3 | $41 |
| Dompe US, Inc. | 1 | $33 |
| Coopervision Inc. | 2 | $31 |
| Eyepoint US, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$487
- Tecnis IOL$389
- Rhopressa$366
- SIMBRINZA$244
- MIEBO$242
- Hydrus Microstent$157
- Hydrus$152
- VYZULTA$142
- Clareon PanOptix Pro$138
- XEN$125
- XIIDRA$125
- Tecnis Simplicity$125
- Clareon$122
- XDEMVY$122
- IACCESS$105
How this compares
$6,247 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 117 | $49,736 |
| Lotemax SmLoteprednol Etabonate | 189 | $47,780 |
| RestasisCyclosporine | 46 | $41,333 |
| ProlensaBromfenac Sodium | 88 | $31,406 |
| Prednisolone Acetate | 855 | $29,554 |
| XiidraLifitegrast | 27 | $26,493 |
| Ketorolac Tromethamine | 786 | $25,061 |
| LumiganBimatoprost | 48 | $21,332 |
| VyzultaLatanoprostene Bunod | 65 | $19,526 |
| Latanoprost | 1,929 | $13,467 |
| Ofloxacin | 827 | $10,253 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 44 | $9,171 |
| CombiganBrimonidine Tartrate/Timolol | 22 | $6,607 |
| Travoprost | 61 | $6,597 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 629 | $4,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate | $470 | $80,591289 claims |
| AbbVieRestasis, Lumigan, Combigan | $774 | $69,273116 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $256 | $49,736117 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $876 | $46,02092 claims |
| AlconSimbrinza | $1,260 | $9,17144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in New Orleans
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Peter KastlNew Orleans$32K
- Benjamin LeeNew Orleans$7K
- Matthew BoltonNew Orleans$5K
- Barry LeaderNew Orleans$5K
- Blake WilliamsonBaton Rouge$443K
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.